Table 1 Baseline characteristics of the study population in Prostate Cancer data Base Sweden (PCBaSe) 3.0
From: How to model temporal changes in comorbidity for cancer patients using prospective cohort data
Active surveillance (n = 7 544) | Radical prostatectomy (n = 9 959) | Curative radio therapy (n = 2 734) | Total (n = 20,237) | |
|---|---|---|---|---|
Age, mean (sd) | 65.4 (6.0) | 61.7 (5.9) | 64.8 (5.7) | 63.5 (6.2) |
Age, n (%) | ||||
≤55 | 362 (4.8) | 1315 (13.2) | 147 (5.4) | 1824 (9.0) |
56–60 | 997 (13.2) | 2280 (22.9) | 435 (15.9) | 3712 (18.3) |
61–65 | 2042 (27.1) | 3314 (33.3) | 781 (28.6) | 6137 (30.3) |
66–70 | 2475 (32.8) | 2433 (24.4) | 846 (30.9) | 5754 (28.4) |
70+ | 1668 (22.1) | 617 (6.2) | 525 (19.2) | 2810 (13.9) |
Educational level, n (%) | ||||
High | 2116 (28.0) | 3327 (33.4) | 731 (26.7) | 6174 (30.5) |
Low | 2198 (29.1) | 2485 (25.0) | 841 (30.8) | 5524 (27.3) |
Middle | 3206 (42.5) | 4109 (41.3) | 1147 (42.0) | 8462 (41.8) |
Missing | 24 (0.3) | 38 (0.4) | 15 (0.5) | 77 (0.4) |
CCI at PCa diagnosis, n (%) | ||||
0 | 6288 (83.4) | 9008 (90.5) | 2276 (83.2) | 17,572 (86.8) |
1 | 734 (9.7) | 596 (6.0) | 295 (10.8) | 1625 (8.0) |
2 | 371 (4.9) | 268 (2.7) | 108 (4.0) | 747 (3.7) |
3+ | 151 (2.0) | 87 (0.9) | 55 (2.0) | 293 (1.4) |
T-stage, n (%) | ||||
T1a | 513 (6.8) | 106 (1.1) | 17 (0.6) | 636 (3.1) |
T1b | 126 (1.7) | 61 (0.6) | 22 (0.8) | 209 (1.0) |
T1c | 5807 (77.0) | 7152 (71.8) | 1796 (65.7) | 14,755 (72.9) |
T2 | 1078 (14.3) | 2621 (26.3) | 887 (32.4) | 4586 (22.7) |
TX/Missing | 20 (0.3) | 19 (0.2) | 12 (0.4) | 51 (0.3) |
N-stage, n (%) | ||||
N0 | 443 (5.9) | 980 (9.8) | 146 (5.3) | 1569 (7.8) |
NX | 7101 (94.1) | 8979 (90.2) | 2588 (94.7) | 18,668 (92.2) |
PSA, mean (sd) | 5.5 (2.0) | 5.8 (1.9) | 6.1 (1.9) | 5.7 (2.0) |
PSA, n (%) | ||||
0–2.0 | 277 (3.7) | 157 (1.6) | 28 (1.0) | 462 (2.3) |
2.1–4.0 | 1578 (20.9) | 1874 (18.8) | 368 (13.5) | 3820 (18.9) |
4.1–6.0 | 2868 (38.0) | 3910 (39.3) | 991 (36.2) | 7769 (38.4) |
6.1–8.0 | 1848 (24.5) | 2568 (25.8) | 838 (30.7) | 5254 (26.0) |
8.1–10 | 973 (12.9) | 1450 (14.6) | 509 (18.6) | 2932 (14.5) |